- WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
May 13, 2026
SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included in the 2026 Dow Jones Best‑in‑Class World Index (DJ BIC World) and the Dow Jones Best‑in‑Class Emerging Markets Index (DJ BIC Emerging Markets).
Through S&P Global's Corporate Sustainability Assessment (CSA), the DJ BIC World Index and the DJ BIC Emerging Markets Index identify sustainability leaders that rank in the top 10% based on their long-term economic, environmental and social performance, selecting from the largest 2,500 global companies in the S&P Global Broad Market Index (BMI) and from the largest 800 companies across 20 emerging markets, respectively.
Based on the 2025 CSA, WuXi Biologics ranked among the top 1% globally within its industry and was included in the S&P Global Sustainability Yearbook for the fourth consecutive year.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are honored to be included in both the DJ BIC World Index and the DJ BIC Emerging Markets Index. This recognition reflects our long‑term commitment to sustainability and the continuous enhancement of our overall performance across environmental, social and governance dimensions. As a global leader in Green CRDMO, WuXi Biologics continues to integrate ESG into its business strategy and operations, delivering innovative end‑to‑end solutions to our global partners. Going forward, we will keep pushing industry boundaries, collaborating with all our stakeholders to promote responsible and sustainable practices throughout the entire value chain."
Over the years, WuXi Biologics' consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies, including MSCI AAA Ratings; EcoVadis Platinum Medals; "A List" status from CDP for Climate Change, Water Security, and Supplier Engagement Assessment; the highest negligible-risk rating by Morningstar Sustainalytics, and designation as a Sustainalytics industry and regional ESG Leader; inclusion in the FTSE4Good Index Series; a "Prime" designation from ISS ESG Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
Story Continues
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
Media
PR@wuxibiologics.com
ESG
esg@wuxibiologics.comCision
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-included-in-2026-dow-jones-bestinclass-world-index-and-emerging-markets-index-302770333.html
View Comments
- Assessing WuXi Biologics (SEHK:2269) Valuation After Recent Share Price Weakness
May 11, 2026
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
Event context and recent share performance
WuXi Biologics (Cayman) (SEHK:2269) has drawn investor attention after a mixed stretch in its share price, with the stock down 1.9% over the past day and 8.1% over the past month.
See our latest analysis for WuXi Biologics (Cayman).
Measured over longer periods, the picture is more mixed, with the share price down over the past quarter but a 1 year total shareholder return of 41.39% contrasting with weaker 3 and 5 year total shareholder returns.
If this kind of swing in sentiment has you thinking about where else growth or recovery stories might be forming, it could be a useful moment to scan 123 healthcare AI stocks.
With revenue and net income both growing at around 13% annually, and the stock still well below its 3-year and 5-year total return levels, is WuXi Biologics undervalued or already pricing in future growth?
Most Popular Narrative: 27.6% Undervalued
WuXi Biologics' most followed valuation narrative puts fair value at HK$45.08 per share, compared with the last close of HK$32.66, and frames that gap around growth in high complexity biologics and expanding capacity.
The accelerated ramp in ADC (antibody-drug conjugates) and bispecific/multi-specific project wins, now making up over 40% of WuXi Biologics' portfolio and driving new, high-complexity business, positions the company as the partner of choice in these fast-growing biologics segments. This supports sustained backlog growth and provides strong visibility into higher late-stage and manufacturing revenues over the next 3-5 years.
Read the complete narrative.
Want to see what justifies that fair value gap? The narrative leans on compound revenue growth, steady margins, and a future earnings multiple that assumes the market stays interested in WuXi's biologics pipeline.
Result: Fair Value of HK$45.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on geopolitical and regulatory risks staying contained, and on global clients not cutting back or in-sourcing work that would weaken WuXi’s revenue base.
Find out about the key risks to this WuXi Biologics (Cayman) narrative.
Next Steps
With sentiment clearly split between short term swings and a longer term opportunity, it makes sense to check the numbers yourself and act while the facts are fresh. To see what the market currently views as the key positives, review the 4 key rewards.
Story Continues
Looking for more investment ideas?
If you are serious about building a stronger portfolio, do not stop at a single stock when a wider set of ideas is only a few clicks away.
Spot potential turnaround stories early by scanning 225 elite penny stocks with strong financials that already show stronger balance sheets and more disciplined financial profiles. Focus your research on companies where price and fundamentals line up, starting with a curated set of 230 high quality undervalued stocks. Prioritise financial strength by reviewing companies in the solid balance sheet and fundamentals stocks screener (389 results) that pair healthier debt levels with more resilient cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 2269.HK.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
Apr 29, 2026
Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation Enhancing governance transparency and effectiveness to create long-term value for all stakeholders Empowering employees and fostering shared value with communities Accelerating climate actions and strengthening environmental stewardship Leading Green CRDMO solutions to support global clients' sustainability journeys
HONG KONG, April 29, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the release of its 2025 Sustainability Report. The report highlights the Company's continued commitment to placing sustainability at the core of its strategy, empowering global clients, advancing innovative biologics to benefit patients worldwide, and creating long-term value for all stakeholders.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "At WuXi Biologics, we believe that long-term business success is built on our responsibility to people, society, and the planet. As a recognized leader in sustainability, we are committed to working collaboratively with all stakeholders to create positive social and environmental impacts, empowering our global clients through end-to-end Green CRDMO solutions, and driving responsible practices across the entire value chain."
Enhancing Governance Transparency and Effectiveness
Guided by a comprehensive sustainability strategy, WuXi Biologics has put in place robust corporate governance structures and well-defined management processes. In alignment with the United Nations Sustainable Development Goals, the company has established science-based, measurable ESG target matrix supported by a detailed roadmap to monitor performance and enable continuous improvement.
WuXi Biologics is committed to open and transparent engagement with stakeholders, and to building long-term, trusted partnerships. As an active participant of the Pharmaceutical Supply Chain Initiative (PSCI), the Company adheres to PSCI principles across Ethics, Human Rights and Labor, Health and Safety, Environment, and Management Systems, and collaborates with global suppliers to promote responsible practices. In 2025, WuXi Biologics achieved ISO 20400 Sustainable Procurement certification, further strengthening supply chain resilience. The Company has established a comprehensive, end-to-end framework to protect intellectual property, trade secrets, and data privacy through institutional, technical, and managerial safeguards, ensuring effective implementation across operations. Meanwhile, the Company continues to enhance its business resilience and risk management capabilities by achieving ISO 22301 Business Continuity Management System certification, supporting stable global operations and public health responses.
Story Continues
Empowering People and Creating Shared Value with Communities
WuXi Biologics highly values the contributions of its global workforce and is proud of its diverse, highly professional talent base representing 51 nationalities. The Company actively supports the career development of women in Science, Technology, Engineering and Mathematics (STEM), with 54% of STEM positions held by female employees, significantly exceeding the industry average.
Community engagement remains a vital component of WuXi Biologics' positive social impact. In 2025, employees contributed over 12,000 volunteer hours in local communities. The Company also promoted closer alignment between employee engagement and community needs by mobilizing volunteer efforts in community initiatives, contributing to greater social resilience.
Driving Equitable Access to Healthcare through Technology and Innovation
By shortening the timeline from molecules to patients, we enable innovative biologics to reach patients faster, at greater scale, and with consistent quality — driving equitable access to healthcare worldwide. Through the establishment of a global, large‑scale, end‑to‑end integrated CRDMO platform, the Company continues to create long‑term value in support of global healthcare equity and improved public health outcomes.
Building on its core technology capabilities, WuXi Biologics actively responds to global public health needs by empowering partners to accelerate the development and manufacturing of innovative therapies for patients around the world. In 2025, the Company has partnered with Instituto Butantan and Fundação Butantan in Brazil to support the scaled commercial manufacturing for the dengue vaccine Butantan-DV, contributing to the strengthening of local public health preparedness. The fill-and-finish facility serving this project has received GMP certification from the Brazilian Health Regulatory Agency (ANVISA).
Rare diseases remain a key focus of the Company's platform‑based innovation. As of the end of 2025, there were 23 rare disease projects on our platform. In May 2025, partner CANbridge Pharmaceuticals received approval from the National Medical Products Administration (NMPA) for velaglucerase-beta for injection (Gaurunning®), marking a significant milestone in advancing innovative rare disease therapies through collaboration.
In addition, the Company is committed to supporting community health through a range of initiatives, including emergency relief, primary healthcare rebuilding, disease assistance, and community health programs, continuously strengthening local healthcare systems and extending healthcare accessibility to the "last mile".
From global public health response to individual care, WuXi Biologics leverages its integrated technology platforms, resilient global network and unified world‑class quality systems to continuously enhance healthcare accessibility, safeguarding the health and well-being of patients worldwide.
Accelerating Actions for Tackling Climate Change and Promoting Environmental Stewardship
The Company continues to enhance environmental stewardship across climate change mitigation, resource efficiency, circular economy practices, ecosystem protection and green innovation.
In 2025, WuXi Biologics introduced a new and ambitious greenhouse gas emission target matrix that was validated by the Science Based Targets initiative (SBTi). The Company also achieved its water management target of reducing water consumption intensity by 30% from the base year 2019 and rolled out its Water Excellence Stewardship program across 10 sites. To support broader industry sustainability, WuXi Biologics published the Green CRDMO White Paper, detailing its green research, development and manufacturing practices, and highlighting energy-saving and carbon-reduction outcomes enabled by green operations.
To drive continuous improvement for operational excellence, WuXi Biologics Business System (WBS) applies lean management principles and integrates with sustainability strategy. In 2025, over 95% of WBS Kaizen projects generated measurable ESG benefits, including reductions in carbon emission, water consumption and waste generation.
Global Impact, Shared Future
WuXi Biologics' consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies. These recognitions include an MSCI AAA ESG rating; an EcoVadis Platinum Medal; inclusion in the Dow Jones Best-in-Class Indices (formerly Dow Jones Sustainability Indices); CDP "A List" status for Climate Change, Water Security, and Supplier Engagement Assessment; the highest negligible-risk ESG rating by Sustainalytics; inclusion in the FTSE4Good Index Series; a "Prime" designation from ISS ESG Corporate Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.
Dr. ChrisChen commented, "Looking ahead to 2026 and beyond, we will build on our strong momentum to accelerate growth, driven by robust research, development and manufacturing capabilities. With sustainability at the core of how we innovate, operate, and grow, WuXi Biologics will continue to empower global clients to bring life-changing therapies to patients worldwide, while delivering long-term value and shared success for all stakeholders in pursuit of a healthier future."
Download 2025 Sustainability Report
https://www.wuxibiologics.com/wp-content/uploads/E_898490_WUXI-BIO_ESG2025_0429_1713_ESS.pdf
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.comCision
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-releases-2025-sustainability-report-advancing-sustainable-growth-and-improving-healthcare-access-302757229.html
View Comments
- WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
Apr 24, 2026
CHENGDU, China, April 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced the structural completion and key equipment arrival at its microbial commercial manufacturing site in Chengdu, marking an important milestone as the company advances toward GMP release for production by the end of 2026.
The microbial manufacturing site, broke ground last June in Wenjiang District of Chengdu, spans approximately 95,000 square meters and is designed for commercial drug substance (DS) and drug product (DP) manufacturing of microbial-derived biologics. A broad spectrum of next-generation therapies, including ADCs, cell therapies, bi-/multi-specific antibodies, and cancer vaccines, leverage recombinant proteins such as polypeptides, enzymes, antibody fragments, nanobodies, and cytokines. These recombinant proteins can be manufactured at scale through microbial fermentation, supported by compatible downstream purification and formulation processes. Microbial fermentation is gaining broad adoption across emerging biologic modalities, driven by its advantages in yield, development speed, scalability, process consistency, and cost efficiency.
Upon completion, the manufacturing site will be equipped with a 15,000 L fermenter, enabling up to 110 DS batches annually, with long-term expansion potential up to 60,000 L. It will also feature China's first dual-chamber lyophilization production line, jointly established with VISEN Pharmaceuticals, along with a vial-filling line that offers commercial DP manufacturing capacity of more than 10 million vials per year, further enhancing its commercial manufacturing capabilities for complex formulations.
In addition, the manufacturing site incorporates integrated automation and digital systems across upstream and downstream operations to support reliable GMP manufacturing, strengthening compliance, operational efficiency, and data integrity. ESG concepts are also embedded into the site's design through green building practices such as sponge city design and the adoption of photovoltaic (PV) modules, enhancing overall resource and energy efficiency.
Dr. Chris Chen, CEO of WuXi Biologics, commented: "The structural completion of our Chengdu microbial manufacturing site represents an important step forward in strengthening our commercial-scale microbial capabilities. Designed to facilitate efficient technology transfer and reliable commercial supply, the site reflects the growing adoption of microbial technologies across emerging modalities and advanced therapies. Combined with our research, development and clinical manufacturing capabilities in Shanghai and Hangzhou, we can provide end‑to‑end CRDMO service from strain development through commercial manufacturing for global pharmaceutical innovators."
Story Continues
Powered by its proprietary E. coli expression system EffiX™, WuXi Biologics achieves recombinant protein titers of up to 15 g/L and delivers a complete CMC package from plasmid DNA to IND filing within six months. Its microbial platform also features a multi‑tier capacity supporting production scale‑up from 15 L, 3000 L to 15,000 L, precisely aligned with preclinical, clinical, and commercial needs. By the end of 2025, WuXi Biologics' integrated microbial fermentation platform has successfully supported the development and manufacturing of 128 molecules.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.comCision
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-chengdu-microbial-commercial-manufacturing-site-achieves-structural-completion-and-key-equipment-arrival-302752824.html
View Comments
- WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
Apr 23, 2026
WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug Product Packaging Center (DPPC) – have received GMP certification from South Korea Ministry of Food and Drug Safety (MFDS). The certification positions WuXi Biologics to provide end‑to‑end commercial manufacturing services, covering both drug substance and drug product, for a bispecific antibody indicated for the treatment of biliary tract cancer.
During the five‑day on‑site inspection, all three facilities successfully passed the MFDS assessment with no critical or major findings, reaffirming WuXi Biologics' robust quality and compliance systems, as well as its proven capability to execute GMP‑compliant large-scale manufacturing for complex biologic programs.
Within WuXi Biologics' global GMP manufacturing network, MFG5, DP2 and DPPC collectively provide integrated, end‑to‑end capabilities spanning drug substance manufacturing, drug product fill‑finish, and customized packaging, enabling efficient commercial supply of innovative biologic therapies.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "Receiving GMP certification from the MFDS demonstrates our continued commitment to the global standards of quality and regulatory compliance. It further strengthens our support for customers across South Korea and the Asia‑Pacific region, while reaffirming our proven domain expertise and systematic strengths in the development and commercial manufacturing of complex biologics, including bispecific antibodies. We will continue to build on our world‑class quality system and end‑to‑end manufacturing capabilities to enable partners to accelerate the delivery of innovative biologics to patients worldwide."
WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's rigorous quality standards. As of the end of 2025, it has successfully passed 46 regulatory inspections, including 22 conducted by the FDA and EMA, and secured 136 facility license approvals. The company also holds an industry-leading record, achieving a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics has passed more than 1,800 GMP quality audits by global clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network. Its world-class quality and compliance capabilities underpin long-standing trust from clients worldwide.
Story Continues
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.comCision
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-receives-south-korea-mfds-gmp-certification-to-enable-commercial-manufacturing-of-bispecific-antibody-therapeutics-302751406.html
View Comments
- WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
Apr 17, 2026
SHANGHAI, April 17, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026.
Marking the sixth consecutive year that WuXi Biologics has received this honor, the recognition highlights the company's unwavering commitment to advancing sustainability throughout its global business operations and value chain, and demonstrates the success of its long-term sustainability strategy and its vision as a Green CRDMO leader.
Morningstar Sustainalytics is a leading independent ESG research, ratings, and analytics provider supporting global investors in the development and implementation of responsible investment strategies. Its 2026 ESG Risk Ratings assessed around 15,000 companies worldwide across 42 industries, with ESG Leader distinctions awarded to companies demonstrating robust ESG risk management and performance relative to their peers across industries and regions. In July 2025, WuXi Biologics was also placed in Sustainalytics' highest ESG rating tier of negligible risk, achieving a top 1% global ranking score.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented: "We are honored to once again be recognized by Morningstar Sustainalytics. As a proactive leader in sustainability, we are committed to collaborating with all stakeholders to create positive social and environmental impacts, empowering our global clients through end-to-end Green CRDMO solutions, and advancing responsible practices across the entire value chain. In addition, we drive equal availability and affordability to innovative therapeutics worldwide by accelerating the journey from molecules to market, and enabling innovative biologics to reach patients faster, at greater scale, and with consistent quality."
Over the years, WuXi Biologics' consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies, including an MSCI AAA Rating; an EcoVadis Platinum Medal; a listing in the Dow Jones Best-in-Class Indices (formerly Dow Jones Sustainability Indices); CDP "A List" status for Climate Change, Water Security, and Supplier Engagement Assessment; inclusion in the FTSE4Good Index Series; a "Prime" designation from ISS ESG Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
Story Continues
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.comCision
View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-biologics-recognized-by-morningstar-sustainalytics-as-industry-and-regional-esg-leader-for-sixth-year-302745605.html
View Comments
- WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
Apr 15, 2026
Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company's robust quality management system
SHANGHAI, April 14, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully achieved ISO 13485:2016 Medical Device Quality Management System certification with zero non-conformities, becoming among the first in China's drug-device combination products sector to obtain this certification. The achievement highlights the company's robust quality system and strong compliance capabilities, reflecting a solid foundation for delivering safe, stable and reliable end-to-end services to clients worldwide.
ISO 13485:2016 is widely recognized as the global gold standard for quality management in the medical device industry. It provides a structured framework to ensure safety, effectiveness and regulatory compliance across the full product lifecycle. The standard spans core elements — such as design and development, risk management, manufacturing process control, traceability, and supplier management — and emphasizes alignment with applicable regulatory requirements. Given the cross-disciplinary nature of drug-device combination products, their development and manufacturing must meet both the stability requirements for active pharmaceutical ingredients and the performance requirements for medical devices. Building on its existing cGMP framework, WuXi Biologics established a combination-product system that is aligned with both pharmaceutical and medical device regulatory expectations.
During the nearly five-day on-site audit, WuXi Biologics demonstrated a strong systems foundation and a comprehensive quality management approach for drug-device combination products, successfully obtaining certification and proving the robustness of its platform for commercial manufacturing.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "Successfully achieving ISO 13485 certification reflects our technical depth and disciplined quality management for drug–device combination products. We will continue to uphold rigorous quality standards and reliable operations to deliver safe, efficient and high-quality solutions for global clients, empowering the development of breakthrough therapies through a trusted CRDMO platform."
WuXi Biologics has continuously strengthened its sustainability and compliance management systems, building an integrated framework that encompasses information security, business continuity, quality management, environmental and occupational safety, energy management, and sustainable procurement. The company has obtained multiple internationally recognized certifications — including ISO/IEC 27001, ISO 22301, ISO 9001, ISO 14001, ISO 45001, ISO 50001, ISO 14064 and ISO 20400 — that verify the strength of WuXi Biologics' foundation for high-quality and sustainable growth.
Story Continues
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, while complex modalities represent more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.comCision
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-achieves-iso-13485-certification-signifying-strong-capabilities-in-drugdevice-combination-product-development-and-manufacturing-302742531.html
View Comments
- Assessing WuXi Biologics (SEHK:2269) Valuation After Choppy Returns And An Undervalued Narrative
Apr 9, 2026
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
What WuXi Biologics (Cayman) SEHK:2269’s recent returns suggest
WuXi Biologics (Cayman) SEHK:2269 has seen mixed share performance, with a 1 day return of 1.0% and a 1 year total return of 84.9%, alongside a 3 year total return decline of 34.0%.
Over the past month the stock shows a 2.9% decline, and over the past 3 months a 4.1% decline, while year to date it sits at a 9.2% gain, indicating a choppy but positive recent backdrop.
See our latest analysis for WuXi Biologics (Cayman).
At a share price of HK$35.54, WuXi Biologics (Cayman) has seen short term share price pressure over the past quarter, alongside a much stronger 1 year total shareholder return. This suggests that earlier pessimism has eased and sentiment has improved.
If WuXi’s move has you reassessing opportunities in healthcare, it can be useful to see what else is setting up for growth across 124 healthcare AI stocks
With WuXi Biologics (Cayman) trading at HK$35.54 and indicators such as a value score of 6 and an intrinsic discount of 38.1%, is the stock still underappreciated, or is the market already pricing in future growth?
Most Popular Narrative: 21.2% Undervalued
WuXi Biologics (Cayman) last closed at HK$35.54, while the most followed narrative sets fair value at HK$45.08, creating a clear valuation gap for investors to assess.
The accelerated ramp in ADC (antibody-drug conjugates) and bispecific/multi-specific project wins, now making up over 40% of WuXi Biologics' portfolio and driving new, high-complexity business, positions the company as the partner of choice in these fast-growing biologics segments. This supports sustained backlog growth and provides strong visibility into higher late-stage and manufacturing revenues over the next 3-5 years.
Read the complete narrative.
Want to see what is baked into that fair value gap? The narrative leans heavily on compounding revenue, steady margins, and a future earnings multiple that assumes continued execution.
Using an 8.03% discount rate, the narrative ties those growth and profitability assumptions together to arrive at a fair value of HK$45.08 per share, which sits above the current HK$35.54 price and supports the view that, on this framework, the stock screens as undervalued.
Result: Fair Value of HK$45.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on overseas demand holding up, because heavy exposure to North America and ongoing geopolitical and regulatory scrutiny around China based CDMOs could quickly challenge that thesis.
Story Continues
Find out about the key risks to this WuXi Biologics (Cayman) narrative.
Next Steps
If this bullish tilt in the story has you curious, it is worth looking at the numbers yourself and stress testing the assumptions that matter most. To see what optimism in the data actually refers to, check out the 5 key rewards
Looking for more investment ideas?
If WuXi Biologics (Cayman) has sharpened your focus, do not stop here. A broader watchlist can help you spot opportunities you might otherwise miss.
Target potential value opportunities early by scanning companies that screen as 241 high quality undervalued stocks before the crowd pays attention. Prioritise resilience by focusing on 299 resilient stocks with low risk scores so you can build a portfolio that leans on steadier business profiles. Hunt for future standouts with the screener containing 577 high quality undiscovered gems and see which lesser known names meet strict quality filters.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 2269.HK.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
Mar 30, 2026
SHANGHAI, March 30, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won "Biologics CDMO of the Year" (Large CDMOs) in the 2026 CDMO Leadership Awards. The company has also been recognized for excellence across multiple categories for "Large CDMO Biologic", including "Best Scaling Support", "Best Analytical Services", "Best Overall Staff", and "Best Project Management". These achievements mark WuXi Biologics' ninth consecutive year winning the CDMO Leadership Awards, underscoring its commitment to advancing integrated technology platforms that accelerate biologics discovery, development, and manufacturing.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are honored to receive the CDMO Leadership Award for the ninth consecutive year. This recognition reflects the continued trust of our global partners and the dedication of our more than 13,000 employees worldwide. By advancing integrated technology platforms, manufacturing excellence, and digital innovation, we remain committed to helping our partners accelerate development, ensure quality and scalability, and bring life‑saving biologics to patients worldwide."
As of the end of 2025, WuXi Biologics has 945 integrated projects on its platform, making it one of the world's largest portfolios of complex biologics. Among them, more than 50% are complex modalities, such as bi-/multi-specific antibodies and ADCs. Supported by innovative technology platforms, deep accumulated know‑how in molecule and process development, and a leading global quality system, WuXi Biologics' timelines from DNA to IND and from IND to BLA have been shortened to 6 months and 15 months, respectively, compared with industry averages of 10–12 months and 24–36 months. From technology transfer to PPQ, the standard timeline is 6 months, with an accelerated timeline of 3.5 months —compared with industry timelines of over 12 months.
WuXi Biologics has developed a holistic strategy to deliver scalable and agile manufacturing solutions that help global clients address evolving market demand. These include the application of large‑volume single‑use bioreactors (SUBs) ranging from 2,000 L and 4,000 L to 5,000 L; the combination of multiple SUBs to enable large‑scale manufacturing of up to 16,000 L; the implementation of innovative intensified bioprocessing such as WuXiUP™ (continuous bioprocessing platform) and WuXiUI™ (ultra-intensified fed-batch bioprocessing platform) to significantly enhance productivity; and the application of WuXia™ TrueSite, a next‑generation targeted integration (TI)-based CHO cell line platform. WuXia™ TrueSite achieves average mAb titers exceeding 8.0 g/L with outstanding expression stability across 60 generations.
Story Continues
Building on its innovative technology platforms, WuXi Biologics consistently leads the industry in manufacturing and bioprocessing excellence. The company has achieved a 100% success rate in PPQ campaigns. It has delivered more than 350 large‑scale batches (6,000 L – 16,000 L per batch) for global partners since 2017. The strong manufacturing track record is underpinned by WuXi Biologics' rigorous, global quality system. As of the end of 2025, the company had successfully passed 46 regulatory inspections, including 22 inspections conducted by the FDA and EMA. The company also holds an industry-leading record with a 100% pass rate for FDA Pre-License Inspection (PLI). Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network, with 136 facility license approvals and a 100% success in GMP inspections. Its world-class quality and compliance capabilities remain the cornerstone of global clients' trust.
WuXi Biologics is also pioneering digital innovation to transform biologics research, development and manufacturing. It has integrated digital innovation across end-to-end R&D, manufacturing, operations, and customer engagement, driving faster timelines, superior quality, and full partnership transparency. By leveraging digital manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain, consistent data integrity and high product quality, while its advanced planning systems have delivered about a 20% improvement in efficiency. Recently, WuXi Biologics launched the industry-leading digital twin platform PatroLab™ to enhance process performance, minimize process risks, shorten development timelines, and ensure consistent, high-quality biologics manufacturing.
The CDMO Leadership Awards and ceremony are produced by Life Science Connect and hosted by Outsourced Pharma. The awards have partnered with the Tufts Center for the Study of Drug Development (Tufts CSDD) to independently design, field, and analyze the research underlying the 2026 awards program.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.comCision
View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-biologics-honored-with-cdmo-leadership-awards-for-ninth-consecutive-year-302728269.html
View Comments
- WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
Mar 25, 2026
SHANGHAI, March 25, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its annual results for 2025, demonstrating record growth and a transformative leap in operational sophistication. The company reported a 16.7% increase in revenue, an IFRS gross profit growth of 30.9%, a 5 percentage-point expansion to 46.0% in gross profit margin and adjusted gross profit surged by25.5% year-on-year. The strong profitable growth has been driven by the continued momentum across research, development and manufacturing, and enhanced operational efficiency.
Pioneering the Intelligent Lab and Factory
One key driver of this year's record growth is the company's rapid transformation into a digitally-native powerhouse. By integrating advanced computational modeling, predictive analytics, and ontology-driven software development, WuXi Biologics has redefined the industry standard for speed, quality, and precision.
These proprietary intelligent systems have streamlined the entire biologics lifecycle, resulting in:
Minimized Complexity: Eliminating manual bottlenecks through integrated, smart-automation workflows. Accelerated Timelines: Utilizing high-speed project-specific data synthesis and interpretation to shorten development cycles and bring life-saving therapies to patients faster. Enhanced Transparency: Providing clients with data-driven "line of sight" from initial molecule discovery through CMC and into commercial manufacturing.
Dr. Chris Chen, CEO of WuXi Biologics commented: "We are redefining the CRDMO role and value as a strategic partner powered by computational insights and agile execution—critical in today's dynamic biopharma innovation landscape. At the heart of this transformation is our unwavering commitment to accelerating our clients' scientific breakthroughs into clinical and commercial success through a fully integrated, end‑to‑end digital platform and predictive modeling, ultimately bringing meaningful benefits to patients worldwide."
Redefining Collaboration: The Next-Generation Client Digital Ecosystem
Complementing its operational advances, WuXi Biologics has launched a secure cloud-based client portal that redefines the collaborative experience. Moving beyond fragmented communication, the portal offers a unified, digitally-integrated workspace.
By providing access to up-to-date milestones, predictive data insights, and comprehensive program planning with fine-grained access controls, the platform ensures that critical information—including manufacturing, quality, and inventory metrics—is available in realistic time. This frictionless access to data eliminates the traditional "push" of manual updates, empowering clients to make faster, more informed decisions. By aligning all stakeholders on a single, synchronized source of truth, the portal strengthens strategic partnerships and accelerates the journey from DNA to IND to BLA without the delays of conventional reporting cycles.
Story Continues
As a global leading digital CRDMO, WuXi Biologics is embedding digital capability and infrastructure across the full biopharmaceutical value chain—turning data, computation, and prediction into faster development, intelligent operations, and more efficient manufacturing. With transparent client portal at the core, the company will continue to redefine the value of CRDMO partnership and help advance a more efficient, predictive, and scalable future for biopharmaceutical innovation—bringing its vision that "every biologic can be made" closer to reality for patients worldwide.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Business: info@wuxibiologics.com
Media: PR@wuxibiologics.comCision
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-reports-record-2025-annual-results-operational-excellence-driven-by-digital-native-architecture-302724708.html
View Comments
